Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma
| Autor: | Ken Sato, Yuichi Yamazaki, Motoyasu Kusano, Daichi Takizawa, Takeshi Hatanaka, Kenji Katakai, Masanobu Yamada, Yasushi Shimada, Satoru Kakizaki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology medicine.medical_specialty Carcinoma Hepatocellular Antineoplastic Agents Gastroenterology 03 medical and health sciences 0302 clinical medicine Hepatic arterial infusion Internal medicine Biomarkers Tumor Internal Medicine medicine Carcinoma Humans Protein Precursors Survival rate Aged Retrospective Studies Aged 80 and over Cisplatin business.industry Liver Neoplasms Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Survival Rate medicine.anatomical_structure 030220 oncology & carcinogenesis Hepatocellular carcinoma Multivariate Analysis Female Prothrombin 030211 gastroenterology & hepatology alpha-Fetoproteins business Biomarkers Progressive disease Artery medicine.drug |
| Zdroj: | Internal Medicine. 55:2163-2171 |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Objective We retrospectively investigated the relationship between the tumor response and serial changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) during hepatic arterial infusion of a cisplatin powder formulation (CDDP powder) in patients with advanced hepatocellular carcinoma (HCC). Methods Seventy-six advanced HCC patients were analyzed. All HCC patients received high-concentration cisplatin (1.43 mg/mL) via the haptic artery at a dose of 65 mg/m(2). AFP and DCP were measured at baseline and four to eight weeks after treatment, and the antitumor responses were evaluated according to the response evaluation criteria in solid tumours (RECIST) criteria after one or two courses of treatment. The patients were classified into two groups, a decreased group and a non-decreased group, according to the change in the serum levels of AFP and DCP at four to eight weeks compared to baseline. Results The response to treatment of the decreased group (n=16) and non-decreased group (n=60) was complete response/partial response/stable disease/progressive disease (CR/PR/SD/PD) in 4/4/5/3 and 1/11/8/40 patients, respectively. The response rate and disease control rate of the decreased group were significantly higher than those of the non-decreased group (p=0.016 and p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|